We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

378 hedge funds and large institutions have $8.35B invested in Royalty Pharma in 2024 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 141 increasing their positions, 127 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

222% more call options, than puts

Call options by funds: $13.5M | Put options by funds: $4.19M

11% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 127

1.94% more ownership

Funds ownership: 68.15% → 70.09% (+1.9%)

7% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 56

0% more funds holding

Funds holding: 378 → 378 (0)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

10% less capital invested

Capital invested by funds: $9.24B → $8.35B (-$885M)

Holders
378
Holders Change
–
Holders Change %
0%
% of All Funds
5.46%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
60
Increased
141
Reduced
127
Closed
56
Calls
$13.5M
Puts
$4.19M
Net Calls
+$9.31M
Net Calls Change
+$4.69M

Top Buyers

1
Swedbank
Swedbank
Sweden
+$300M
2
BlackRock
BlackRock
New York
+$50.2M
3
BGIM
Brandywine Global Investment Management
Pennsylvania
+$45.4M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$29.5M
5
Invesco
Invesco
Georgia
+$29.5M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$159M
2
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$81.4M
3
Millennium Management
Millennium Management
New York
-$64.2M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$15.8M
5
CSS
Cubist Systematic Strategies
Connecticut
-$14.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Capstone Investment Advisors
401
Capstone Investment Advisors
New York
– -$542K -17,841 Closed
AM
402
AGF Management
Ontario, Canada
– -$506K -16,657 Closed
BRWA
403
B. Riley Wealth Advisors
Florida
– -$436K -16,050 Closed
AI
404
AdvisorShares Investments
Maryland
– -$477K -15,717 Closed
CT
405
ClearAlpha Technologies
Connecticut
– -$399K -13,137 Closed
BP
406
Ballentine Partners
Massachusetts
– -$381K -12,541 Closed
DC
407
Diametric Capital
Massachusetts
– -$360K -11,851 Closed
AC
408
ASB Consultores
Florida
– -$358K -11,798 Closed
ACM
409
Aquatic Capital Management
Illinois
– -$340K -11,200 Closed
Koshinski Asset Management
410
Koshinski Asset Management
Illinois
– -$324K -10,671 Closed
Renaissance Technologies
411
Renaissance Technologies
New York
– -$309K -10,190 Closed
SC
412
Saybrook Capital
North Carolina
– -$273K -9,000 Closed
SRL
413
Scientech Research LLC
New Jersey
– -$273K -8,973 Closed
EI
414
Ethic Inc
New York
– -$266K -8,745 Closed
AC
415
AXQ Capital
New Jersey
– -$240K -7,900 Closed
UFA
416
US Financial Advisors
Massachusetts
– -$237K -7,815 Closed
TCM
417
Teza Capital Management
Illinois
– -$230K -7,576 Closed
LSAG
418
Lake Street Advisors Group
New Hampshire
– -$227K -7,464 Closed
CB
419
Commerce Bank
Missouri
– -$224K -7,379 Closed
Cetera Investment Advisers
420
Cetera Investment Advisers
Illinois
– -$222K -7,318 Closed
ATC
421
Argent Trust Co
Tennessee
– -$220K -7,259 Closed
Wealth Enhancement Advisory Services
422
Wealth Enhancement Advisory Services
Minnesota
– -$219K -7,197 Closed
NYLIM
423
New York Life Investment Management
New York
– -$207K -6,800 Closed
Simplex Trading
424
Simplex Trading
Illinois
– -$185K -6,672 Closed
First Manhattan
425
First Manhattan
New York
– -$106K -3,500 Closed
14 15 16
17
18

RPRX Hedge Fund Activity: Q2 2024 in Review

378 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q2 2024, worth a combined $8.35B — down 9.6% from $9.24B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new RPRX positions and 56 closed out — a net gain of 4 holders — while 141 added to existing stakes and 127 trimmed.

The largest buyer was Swedbank, opening a new position worth an estimated $300M. The largest seller was Fidelity Investments, cutting an estimated $159M.

  • 378 institutional investors held Royalty Pharma (RPRX) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $8.35B of Royalty Pharma stock for Q2 2024, down 9.6% quarter-over-quarter.
  • 60 funds opened new Royalty Pharma positions in Q2 2024 and 56 closed out, a net change of +4 holders.
  • The largest Royalty Pharma buyer in Q2 2024 was Swedbank, an estimated $300M added.
  • The largest Royalty Pharma seller in Q2 2024 was Fidelity Investments, an estimated $159M sold.

Based on aggregated 13F filings for Q2 2024.